COMPLEX TREATMENT OF IRON DEFICIENCY ANEMIA WITH OBESITY IN WOMEN

Authors:

Abstract:

The purpose of the study was to determine the effect of the inclusion of quercetin in the complex treatment of sick women in IDA with O for hematological parameters and QOL. 30 women were evaluated in a IDA with concomitant O that were distributed to the main group - 15 patients (n = 15) taking the basic treatment of iron sulfate with an additional oral administration of quercetin and a control group of 15 patients ( n = 15) who received baseline treatment. The comparison group consisted of 10 women (n = 10) of patients with IDA without O on baseline treatment. Evaluated hematological parameters and QOL by questionnaire SF-36. All patients were females with an average age of 40.3 ± 7.59 years. In the distribution of patients by the cause and the severity degree of IDA, there is no probable difference between the groups. In the course of treatment, a significant discrepancy of the indicators on the role of physical functioning (RFF) and viability (G) scales was noted for 60±3 days in the main group compared to the control group (p<0,05), in the absence of any discrepancy with the comparison group (p>0,05). Conclusion. Incorporation of quercetin into a complex of treatment of iron deficiency anemia with obesity improves the physical component of quality of life quality on the scales of the RFF and G the SF-36 questionnaire in women with iron deficiency anemia with obesity.

Keywords:

iron deficiency anemia obesity quality of life.

References:

1. Fadieieva HA. Kliniko-imunolohichna efektyvnist zastosuvannia kvertsetynu u khvorykh na bronkhialnu astmu u poiednanni iz vistseralnym ozhyrinniam. Visnyk Sumskoho derzhavnoho universytetu. Seriia Medytsyna. 2009; 2 (T.1): 162-167.
2. Bekri S., Gual P. Increased adipose tissue expression of hepcidin insevere obesity is independent from diabetes and NASH. Gastroenterology. 2006; 131: 788-796.
3. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015; 372:1832-1843.
4. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003; 102(3):783–788.
5. Kaidashev IP. NF-kB activation as a molecular basis of pathological process by metabolic syndrome. Fiziol Zh. 2012; 58(1):93-101. Review. Ukrainian.

Publication:

«World of Medicine and Biology» Vol. 13 No. 62 (2017) , с. 63-66
УДК 616.155.194-06:616-056.52]-055.2-085:615.356:613.99

DOI:

https://doi.org/10.26724/2079-8334-2017-4-62-63-66